In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $4.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising preclinical data for Actinium Pharmaceuticals’ ATNM-400 in prostate cancer. The data presented at the Society of Nuclear Medicine & Molecular Imaging annual conference highlighted ATNM-400’s potent efficacy in enzalutamide-resistant prostate cancer models and its enhanced cell-killing ability when used in combination with other treatments.
Additionally, ATNM-400 demonstrated superior tumor control compared to standard radiotherapies and enzalutamide, even in tumors that had previously been treated with PSMA-directed therapies. The company’s management also indicated a strong financial position, with a cash runway extending into 2028, providing a stable foundation for ongoing research and development. These factors collectively contribute to Pantginis’s positive outlook on Actinium Pharmaceuticals’ stock.